Lupus pernio is a specific sarcoidosis skin lesion characterized by violaceous indurated plaques primarily affecting the central face. It is a hallmark of chronic disease, and treatment remains challenging because conventional therapies often fail.
Correspondence: Dr Dalm, Department of Immunology, Erasmus Medical Center, Gravendijkwal 230, 3015 CE Rotterdam, the Netherlands (firstname.lastname@example.org).
Conflict of Interest Disclosures: None reported.
Funding/Support: The lenalidomide was provided for our patient by Celgene Corporation without charge; the drug is not registered in the Netherlands for the treatment of sarcoidosis and so its use in this context is not covered by health insurance.
Role of the Sponsor: Celgene Corporation had no role in the design and conduct of the study; in the collection, analysis and interpretation of the data; or in the preparation, review, or approval of the manuscript.
Figure. Clinical images of our patient with lupus pernio. A, Frontal and coronal views prior to start of therapy with lenalidomide. B, Frontal and basal views 3 months after initiation of lenalidomide treatment, demonstrating an impressive improvement of skin lesions.
Thank you for submitting a comment on this article. It will be reviewed by JAMA Dermatology editors. You will be notified when your comment has been published. Comments should not exceed 500 words of text and 10 references.
Do not submit personal medical questions or information that could identify a specific patient, questions about a particular case, or general inquiries to an author. Only content that has not been published, posted, or submitted elsewhere should be submitted. By submitting this Comment, you and any coauthors transfer copyright to the journal if your Comment is posted.
* = Required Field
Disclosure of Any Conflicts of Interest*
Indicate all relevant conflicts of interest of each author below, including all relevant financial interests, activities, and relationships within the past 3 years including, but not limited to, employment, affiliation, grants or funding, consultancies, honoraria or payment, speakers’ bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued. If all authors have none, check "No potential conflicts or relevant financial interests" in the box below. Please also indicate any funding received in support of this work. The information will be posted with your response.
Some tools below are only available to our subscribers or users with an online account.
Download citation file:
Web of Science® Times Cited: 1
Customize your page view by dragging & repositioning the boxes below.
More Listings atJAMACareerCenter.com >
Enter your username and email address. We'll send you a link to reset your password.
Enter your username and email address. We'll send instructions on how to reset your password to the email address we have on record.
Athens and Shibboleth are access management services that provide single sign-on to protected resources. They replace the multiple user names and passwords necessary to access subscription-based content with a single user name and password that can be entered once per session. It operates independently of a user's location or IP address. If your institution uses Athens or Shibboleth authentication, please contact your site administrator to receive your user name and password.